Home » Newsletters » BioWorld Science

BioWorld Science

Dec. 29, 2017

View Archived Issues

ZPIV demonstrates safety and immunogenicity in preliminary analysis of three phase I studies

CStone seeks Australian clinical trial approval to begin studies of CS-1003 and CS-3006

Patient recruitment ongoing in phase II trial of CR-6086

Phase I study of C188-9 enrolling patients with advanced cancer

FDA approves expanded indication for Procysbito to include children 1 year of age and older

Treatment with CRISPR-Cas9 improves motor function and extends survival in mouse model of ALS

Descartes-08 cells demonstrate promising antitumor effect in preclinical models of multiple myeloma

Fervent Pharmaceuticals submits IND in U.S. for FP-101

CD229 CAR T cells demonstrate strong cytotoxic activity, selectivity in models of multiple myeloma

Phase III EMBRACA study meets primary endpoint of PFS with talazoparib over chemotherapy

Caveolin-1 as a potential novel target with antimetastatic function in macrophages

GAK as a potential new therapeutic target for FBXW7-deficient tumors

TherapeuticsMD submits NDA for TX-001-HR to treat menopausal vasomotor symptoms

Odonate Therapeutics announces initiation of phase III CONTESSA study

BiondVax Pharmaceuticals planning phase III study of universal flu vaccine

FDA grants priority review to Epidiolex NDA, GW Pharmaceuticals submits MAA in Europe

Brazilian approval for Biocon and Mylan's trastuzumab biosimilar

Genexine signs licensing agreement with I-Mab for HyLeukin in Greater China

HTG Molecular Diagnostics in new master collaboration agreement with Merck KGaA

FDA approves Dermapace System to treat diabetic foot ulcers

Gilead Sciences patents farnesoid X receptor agonists

Infinity Pharmaceuticals describes PI3Kgamma/delta inhibitors

Janssen Biotech reports development of GM-CSF variants for treatment of IBD

Medshine Discovery patent describes beta-lactamase inhibitors

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 27, 2026.
Detecting the invisible: minimal residual disease at AACR 2026
BioWorld Science
Minimal residual disease (MRD) has become a central concept in modern oncology, reshaping how clinicians evaluate response, relapse risk and treatment precision....
A free gene therapy? Regeneron’s Otarmeni approved for hearing loss
BioWorld
Children and adults with a type of congenital hearing loss now have a free treatment option, with the U.S. FDA’s accelerated approval of Regeneron Pharmaceuticals...
AACR 2026: The age of agentic AI in oncology
BioWorld Science
New Approach Methodologies (NAMs) for drug development are transforming biomedical research by replacing or complementing animal models. More than 90% of...
Chengdu Mfs Pharma synthesizes new compounds for pain
BioWorld Science
Chengdu Mfs Pharma Co. Ltd. has prepared and tested compounds for the potential treatment of pain, sleep disorder and status epilepticus epilepsy as well as for...